GLUT1/EGFR-IN-1

GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of GLUT1 and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research[1].

Product Specifications

CAS Number

[2393787-80-7]

UNSPSC

12352005

Target

Apoptosis; EGFR; GLUT

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Membrane Transporter/Ion Channel; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/glut1-egfr-in-1.html

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C2C=C(C=C1OCC3=CC=CC=C3)C(NC4=CC=C(C5=C4)N=CN=C5NC6=CC=C(C=C6)C)=O)C7=C(C=CC=C7C2=O)OCC8=CC=CC=C8

Molecular Formula

C44H32N4O5

Molecular Weight

696.75

References & Citations

[1]Wang C, et al. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma. Eur J Pharm Sci. 2024 Jul 1;198:106789.